Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), linear decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), linear decrease (Expand Search)
-
2661
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
2662
-
2663
-
2664
-
2665
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2666
-
2667
-
2668
-
2669
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2670
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2671
-
2672
-
2673
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2674
-
2675
-
2676
-
2677
-
2678
-
2679
-
2680